RxDoctor Payments Data

Mary Hill, MD

Family Medicine · Fresno, CANPI 1356335053

Payments from drug & device makers

$826in general payments, 2019–2025

Across 33 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$355
  • Johnson & Johnson$90
  • Abbott$49
  • GSK$43
  • Lilly USA, LLC$38
  • Pfizer$35
  • plus $218 from 9 others

What the payments were for

  • Food & beverage$826100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$826 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$31,118
Medicare patients
170
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin113$115,647
OzempicSemaglutide47$60,037
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$37,047
FarxigaDapagliflozin Propanediol23$31,838
TradjentaLinagliptin12$15,156
EliquisApixaban17$14,682
SymbicortBudesonide/Formoterol Fumarate17$4,856
PremarinEstrogens, Conjugated13$4,681
Estradiol39$4,109
Levothyroxine Sodium244$3,387
Rosuvastatin Calcium139$2,073
Atorvastatin Calcium214$1,953
Bupropion XlBupropion Hcl49$1,560
Gabapentin66$1,544
Albuterol Sulfate HfaAlbuterol Sulfate30$1,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$20$60,03747 claims
GSKTrelegy Ellipta$43$37,04747 claims
AstraZenecaFarxiga, Symbicort$355$36,69440 claims
PfizerEliquis, Premarin$35$19,36330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →